Clinical research & EBM · Reference
What is a placebo?
A placebo is an inert or sham intervention, with no specific therapeutic action, used as a comparator in clinical trials. By giving the control group something indistinguishable from the real intervention, researchers can separate the effect of the intervention from expectation and the natural course of a condition.
Why placebos are used
A placebo serves as a methodological control, not a treatment. Many conditions improve over time on their own, and the mere act of receiving care can change how people feel and report symptoms. Without a comparison group receiving an indistinguishable but inert intervention, researchers could mistake these non-specific changes for the effect of the intervention under test. By comparing the active group against a placebo group, a trial isolates the part of any improvement that is specifically due to the intervention. This is why placebo-controlled designs are central to evaluating new interventions.
Placebos and blinding
Placebos are essential to blinding. If the control group received nothing, participants and investigators would know who was getting the active intervention, reintroducing the very biases the design is meant to remove. A convincing placebo — matched in appearance, taste or procedure — keeps the allocation concealed, supporting a randomized controlled trial in which neither participants nor assessors can tell the groups apart. The placebo is thus the practical mechanism that makes double-blind comparison possible.
Placebo response and ethics
Improvement seen in a placebo group is often called the placebo effect, although it also reflects natural recovery and measurement artefacts. Distinguishing the genuine response to expectation from these other factors is itself a methodological challenge. Use of placebos is governed by research ethics: a placebo control is generally acceptable when no proven effective alternative is being withheld, but where an established effective option exists, ethical guidance such as the Declaration of Helsinki constrains the use of placebo alone.
Key facts
At a glance
- Definition: Inert or sham intervention used as a comparator
- Purpose: Control for expectation and natural course
- Enables: Blinding in randomized controlled trials
- Related to: The placebo effect (improvement from expectation)
- Ethics: Governed by the Declaration of Helsinki
Common questions
FAQ
What is the role of a placebo in a clinical trial?+
A placebo is the inert comparator given to the control group so that the trial can separate the specific effect of the intervention from expectation and the natural course of a condition. It is a methodological control, not a treatment.
How does a placebo help with blinding?+
Because a placebo is made to look identical to the active intervention, participants and investigators cannot tell who received which. This concealment supports double-blinding and prevents the knowledge of allocation from biasing behaviour or outcome assessment.
Is it always ethical to use a placebo?+
A placebo control is generally acceptable when participants are not denied a proven effective alternative. Where an established effective option exists, research-ethics guidance such as the Declaration of Helsinki limits the use of a placebo-only comparison.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
